← All trials
NCT03676140
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2018
- Primary completion
- Dec 31, 2018
- Completion date
- Jan 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 20000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Lihir Medical CentreLead sponsor
- Government of Papua New GuineaOverall official - principal investigator
- University of LondonCollaborator
- Lihir Medical CentreReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.